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Abstract
Introduction: The increasing use of genetic testing for BRCA1/2 and other pathogenic variants
in the management of women with breast and ovarian cancer necessitates increased genetic
literacy in oncology healthcare professionals. This pilot study aimed to evaluate an online
training program to increase genetic literacy and communication skills in Australian oncology
healthcare professionals tasked with discussing and coordinating mainstream genetic testing
with breast and ovarian cancer patients. Materials and methods: A training website with
embedded videos was developed. This study assesses the website’s acceptability and userfriendliness; suggestions for improvement were also elicited.

Oncology healthcare

professionals were recruited through relevant professional organisations, invited to the study
by email, asked to work through the website and then complete an online questionnaire.
Results: Thirty-two oncology healthcare professionals completed the questionnaire after
viewing the website. Nearly all participants were satisfied with the information contained in
the program (very satisfied: n=14/32, 44%, satisfied: n=17/32, 53%, neither satisfied nor
dissatisfied: n=1/32, 3%) and reported that they had gained new skills (n=29/32, 94%) and had
increased confidence (n=29/31, 94%) in communicating with breast and ovarian cancer
patients about genetic testing. More than 93% (28/30) of participants endorsed the online
program as clearly presented, informative, relevant and useful. Conclusion: This pilot study
demonstrated high feasibility and acceptability of the training program to increase genetic
literacy and communication skills in oncology healthcare professionals discussing genetic
testing with breast and ovarian cancer patients. Further evidence from a randomised trial is
needed to evaluate effects on changing clinical practice, improving patient outcomes, and costeffectiveness.
Key words: Communication training, online training, oncology healthcare professionals, genetic
testing, BRCA1, BRCA2, breast cancer, ovarian cancer
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Introduction
Germline testing of cancer susceptibility genes refers to testing for specific, high-penetrance
pathogenic variants. This includes pathogenic variants in the breast/ovarian cancer genes
BRCA1 and BRCA2 (BRCA1/2). Identification of carriers of these variants can save lives
because it allows for: i) identification of affected women who may benefit from targeted
treatment options [1-3]; ii) prevention of other primary cancers; and iii) the opportunity for
predictive testing in biological relatives to enable implementation of preventative strategies in
those identified as carriers [4-6].
Traditionally, genetic testing for cancer susceptibility and communication of the results
have been managed exclusively through genetics-trained specialists at familial cancer clinics.
In recent years, there has been a paradigm shift with the provision of genetic counselling and
testing increasingly offered by non-genetics trained specialists, often referred to as
‘mainstreaming’. This shift in practice benefits patients and their families through potentially
increased and faster access to appropriate publicly funded germline genetic testing [7, 8].
Several factors have prompted the adoption of a mainstreaming model of genetic
testing. Australian [9] and international guidelines [10] on germline BRCA1/2 genetic testing
have expanded to include other indications in addition to the classic feature of a strong family
history [11, 12], increasing the number of women for whom genetic testing is recommended.
These additional indicators include younger age at breast cancer diagnosis, presence of bilateral
breast cancer, membership in an ethnic group with a high incidence of founder mutations (for
example, Ashkenazi Jewish background), as well as tumour tissue characteristics, in particular
triple negative breast cancer (estrogen and progesterone receptor and HER2 negative) [11, 12].
Second, the availability of targeted treatment, poly (ADP-ribose) polymerase (PARP) inhibitor,
for platinum-sensitive BRCA-mutated high-grade epithelial ovarian cancer patients [13] means
that it is more time-efficient for oncology specialists to request these tests without needing to
4

refer the patient to a specialised genetics clinic. BRCA1/2 testing may also be of assistance in
planning surgical therapy for women with breast cancer, whilst receiving neoadjuvant systemic
therapy [14]. The falling costs of all types of genetic tests [15] have also contributed to the
rapidly increasing number of tests ordered. Finally, in Australia one driver of a shift towards
mainstreaming is the recent provision of government (Medicare) funding for germline testing
of breast and ovarian cancer predisposition genes, which may be requested by a non-genetics
specialist [13, 16].
Communicating germline genetic test results can be challenging, in particular, when
variants of uncertain significance are found, or when no pathogenic variant is identified to
explain a significant and penetrant family history suggestive of an underlying high-risk gene.
Healthcare professionals obtaining consent for germline mutation analysis from patients face
the challenge of counselling about possible outcomes to ensure informed choice.

This

requirement and the demands of addressing a shared family risk require skills in genetic literacy
and in genetic risk communication.
Numerous overseas studies have shown that non-genetics healthcare professionals,
including medical oncologists [17], have insufficient knowledge of genetics, are mostly illprepared to counsel patients regarding germline genetic test results and report unmet
educational needs [18-21]. Similarly, a recent Australian needs assessment of medical
specialists from diverse medical backgrounds highlights a need for continuing genomic
education that is targeted to the speciality [22]. Non-genetics healthcare professionals are often
poor at accurate and detailed family history documentation [8, 23] and risk communication
[24] and reportedly lack adherence to guideline-based practices regarding BRCA1/2 testing
[25]. Finally, and possibly most importantly, misinterpretation of test results may result in
incorrect management [19, 25]. Unless specialists receive education and training in genetic
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literacy and communication skills, their genetic care of individual patients may be unhelpful
and possibly even harmful.
Mainstream genetic testing differs from traditional genetic testing because it is
treatment-focused - it has the potential to provide a treatment advantage to the individual. As
such, most people want testing. In our previous studies in both the breast cancer and ovarian
cancer setting, we demonstrated that women unanimously commented that the decision to
undergo testing was a “no-brainer” [26-29]. As such, the communication skills required in the
context of mainstream testing need to predominately focus on conveying genetic testing results
to patients, in contrast to the communication skills required in relation to traditional genetic
testing, which encompass tailored counselling to promote informed and shared decisionmaking regarding whether to have or postpone testing.
Genetic literacy and communications skills are a complementary set of proficiencies:
Genetic literacy includes knowing the indications for having particular germline genetic tests
and core concepts to understand genetic risk, while communication skills focus on skills for
conveying complex and nuanced genetic testing results to patients and family members. Given
the rapidly increasing number of genetic tests being offered by oncology healthcare
professionals, there is an urgent need for the genetic literacy and communication skills of these
professionals to be enhanced to ensure optimal translation of genetic research findings into
mainstream healthcare [22, 30, 31]. A meta-analysis [32] and other reviews [33, 34] of online
training interventions for specialists conclude that such interventions are educationally
beneficial and can achieve outcomes similar to those of traditional teaching methods, with
studies favouring online instructions compared to traditional methods [32]. Therefore, online
training of oncology healthcare professionals seems particularly well suited to achieve the
desired advances in genetic literacy and communication skills.
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This article describes the development and pilot testing of an online training program
to increase genetic literacy and communication skills to convey BRCA1/2 genetics testing
results in oncology healthcare professionals discussing genetic testing with breast and ovarian
cancer patients. The focus of the website was on genetic testing for BRCA1/2 pathogenic
variants because of the rarity of pathogenic variants related to breast and/or ovarian cancer
predisposition in other genes, and because at the time of the study targeted treatments covered
by Medicare funding such as PARP inhibitors were only available for BRCA1/2-mutated
platinum-sensitive relapsed high-grade serous epithelial ovarian cancer [1-3]. However, the
online training module was always written with the intention of expanding it at a later time to
include other genes – not just breast and ovarian cancer genes, but also bowel cancer genes and
other genes.

Methods
Development of website content
The online training program was developed by a multidisciplinary committee, including
healthcare professionals with expertise in genetic counselling, clinical genetics and oncology
and an expert in healthcare communication. The website is available for viewing at the
following URL: https://www.mainstreamgenetictesting.com.au.
The content of the website was based on a previously developed face-to-face workshop
training module for oncology healthcare professionals to enable mainstreamed genetic testing
[35]. This module in turn was informed by a formerly published mainstreaming training
module [7], our previous research findings [28, 36], national guidelines regarding who was
eligible for testing [9] and expert opinion.

7

Format of the website
The website was developed to meet the needs and demands of non-genetics specialist oncology
healthcare professionals and to enable access to an online educational tool for use at anytime
and anywhere. The website is built on the Word Press platform. It utilises the LearnDash
learning management system (LMS) and contains two SCORM 2014-compliant/Tin Canny
modules, developed using Articulate Storyline 360. The website contains two modules. Module
1 provides an introduction to mainstream genetic testing, and Module 2 covers the mainstream
genetic testing process.

Embedded videos
Modules 1 and 2 include a total of eight embedded videos, which are arranged thematically
throughout the modules and are between 0:38 min and 4:00 min in length. They feature a
genetic counsellor, an oncology nurse and a medical oncologist, who are well-known
Australian and UK-based experts in BRCA1/2 genetic testing.

Links to resources
Links to resources are provided to: the national guidelines on BRCA1/2 genetic testing [9];
Medicare Benefits Schedule items to ensure correct ordering of tests [13, 16]; a list of local
familial cancer clinics/genetics services; and a guide to using the Manchester scoring system
to assess a patient’s eligibility for genetic testing under the Medicare Benefits Schedule,
adapted from Evans et al. [37]. Other tools and resources to support mainstream genetic testing
were based on the developed face-to-face workshop training module for oncology healthcare
professionals to enable mainstreamed genetic testing [35]. These tools and resources included:
a flow chart describing the mainstream genetic testing process, a patient consent form template,
a genetic test request form template and a sample script to help guide the introduction of
8

mainstream genetic testing to patients. Two patient education brochures are also included: (i)
on BRCA1/2 genetic testing in women newly diagnosed with ovarian cancer (developed as part
of the previous workshop training [35]), and (ii) on treatment-focused genetic testing for
women newly diagnosed with breast cancer [27]. Finally, a fact sheet on life insurance and
genetic testing is included.

Content of the website
Module 1: Introduction to mainstream genetic testing
Module 1 consists of 19 content screens covering: an introduction to mainstream genetic testing
of BRCA1/2, fundamentals of genetics and an overview of genetic testing. The content screens
are followed by reinforcing activities consisting of seven screens with open-ended, true/false
questions and multiple-choice items. See Figure 1 for examples of reinforcing activities.
Instructions ask users to check their understanding of the information provided in the module
by checking their answers against the summary screens following these reinforcing questions.
Module 1 includes two summary screens.

[Insert Figure 1 about here]

Module 2: The mainstream genetic testing process
Module 2 consists of 34 content screens covering: tools and resources to support mainstream
genetic testing of BRCA1/2; assessment that the patient meets the eligibility criteria for
Medicare funded genetic testing; introduction to mainstream genetic testing, consenting
patients for testing and organising the test; receiving, interpreting and giving genetic test
results; referral to the local familial cancer clinic/genetic service; and questions patients are
asked during the mainstream genetic testing process. The content screens are once again
9

followed by reinforcing activities consisting of eight screens with questions, followed by three
summary screens.

Evaluation of the communication skills and genetic literacy training program
Participants
Individuals were deemed eligible to participate if they were oncology healthcare professionals
and provided care to oncology patients in Australia, including medical or radiation oncologists,
gynae-oncologists, surgeons, and oncology nurses. These professional groups were included
because they were either already discussing genetic and genomic testing with patients or were
likely to do so in the future.

Recruitment
Oncology healthcare professionals were identified through relevant professional organisations:
Clinical Oncological Society of Australia, Medical Oncology Group of Australia, Royal
Australian and New Zealand College of Radiologists, Royal College of Surgeons and Cancer
Nurses Society of Australia. Invitation emails were sent via these organisations or invitations
were included in the organisations’ newsletters. Interested healthcare professionals were
directed to click on a link to access the training program, work through the website, access the
link to the Participant Information and Consent form and then asked to immediately complete
the survey. The online survey software Qualtrics was used to administer these surveys.

Measures
The online survey was adapted from a previously used survey instrument [38] (Supplementary
File 1). It included the following measures:
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Socio-demographic and professional details. Gender, age, professional background, work
setting, length of practice in current field as well as current frequency of discussing genetic
testing with patients were assessed.
Experience of using and satisfaction with the online program. Fifteen items with Likert-type
and open-ended response options assessed: use of the program; preferences for length of
program; satisfaction with different components of the website including: perceived relevance,
usefulness and acceptability; and perceived helpfulness of program in terms of improving
understanding and skills relating to communicating with breast and ovarian cancer patients
about genetic testing. In addition, participants were asked to rate (using Likert-type response
options) each of the two modules in terms of whether they were: clearly presented, informative,
adequate, appropriate, relevant to their work, and useful to their work.
Self-rated competence in communicating with breast and ovarian cancer patients about genetic
testing. Five items, adapted from two previous communication skills training studies [39],
assessed self-rated competence in communicating with patients about genetic testing, using
Likert-type response options anchored from ‘Strongly disagree’ to ‘Strongly agree’ (for
example, ‘Now that I have completed the training program, I feel confident in communicating
with breast and ovarian cancer patients about genetic testing’).

Data analysis
Data were analysed using the Statistical Program for the Social Sciences Version 25. Basic
descriptive statistics, including means, medians, percentages, ranges and standard deviations
were calculated to describe the sample and responses.

Results
Socio-demographic and professional characteristics
11

Thirty-two individuals completed the questionnaire. Demographic and professional
characteristics of participants are shown in Table 1. Fourteen (44%) were medical oncologists
or medical oncology trainees, 1 (3%) was a gynae-oncologist, 5 (16%) were surgeons, 11 (34%)
were nurses and one was an oncology pharmacist. Twenty-five (75%) were female. Five (16%)
reported never discussing genetic testing with patients, nine (28%) discussed genetic testing 15 times a year, while five each discussed it 6 to 10 (16%) and 11-20 (16%) times a year, and 8
>20 (25%) times a year.

[Insert Table 1 about here]

Experience of using, and overall satisfaction with, the online program
All participants completed all sections of the program, and 75% completed it in one sitting.
The time taken to complete the program varied, with three (9%) taking <30 minutes, eight
(25%) 31-45 minutes, 14 (44%) 46-60 minutes and seven (22%) 61-90 minutes. Thirty (94%)
believed that the length of the online training program was about right, and two (6%) thought
it was too short. Fourteen (44%) were very satisfied, and 17 (53%) were satisfied with the
information contained in the program, while one (3%) was neither satisfied nor dissatisfied.
Similarly, 8 (25%) of participants reported finding the program “extremely helpful”, 19 (59%)
“very helpful” and five (16%) “satisfactory” in giving them an understanding of issues relating
to communicating with breast and ovarian cancer patients about genetic testing. Twenty-nine
(94%) stated that they gained new skills from the program relating to communicating with
breast and ovarian cancer patients about genetic testing. Twenty-two (73%) percent believed
that the videos in the program were useful in showing the issues related to genetic testing as
experienced by oncology healthcare professionals, while one (3%) did not believe so and seven
(23%) were unsure. Thirty participants (100%, disregarding two participants where data were
12

missing) considered that the online format was appropriate for the program, that the additional
resources contained in the training program were easily accessible, that the program was easy
to use, and that they would recommend it to their professional colleagues.

Satisfaction with the modules of the online program
Figure 1 displays the satisfaction with the modules of the online program. Between 70% and
90% of the participants thought that both modules were “very” clearly presented, informative,
appropriate, relevant and useful for participants’ work, while between 10% and 33% provided
an endorsement of “somewhat” regarding these attributes.

[Insert Figure 2 about here]

Self-rated competence in communicating with breast and ovarian cancer patients about genetic
testing
Table 2 shows the responses to five items, which assessed self-rated competence in
communicating with breast and ovarian cancer patients about genetic testing. For example, 19
(61%) of participants “somewhat agreed” and 10 (32%) “strongly agreed” they were confident
in communicating with breast and ovarian cancer patients about genetic testing after they
completed the program, while 2 (7%) “neither agreed nor disagreed”.

[Insert Table 2 about here]

Suggestions for improvements
A number of participants made suggestions for improvements in response to open-ended
questions related to several themes: (i) resources (e.g. offer additional links to gain more in13

depth knowledge for those who are interested, provide the option of downloading slides or a
summary of the training website); (ii) provide more opportunities for clinicians who are time
poor (e.g. shorten the videos to enable those who are time poor to watch them); (iii)
generalisability (e.g. offer more information about genetic testing in other contexts, for example
BRCA1/2-positive pancreatic cancer, as well as other inherited conditions and provide training
which targets pathogenic variants in genes other than BRCA1/2); (iv) practice/rehearsal (e.g.
provide an opportunity to practice Manchester scoring [37]; (v) complex scenarios (e.g. provide
information on how to proceed if patients have family members who have already been tested
and have been found to be negative, but the family is still at high risk); and (vi) updates (e.g.
offer updates to the program to be emailed to people who have completed the program to allow
them to keep their knowledge current).

Discussion
While online training programs have been developed for a range of healthcare professionals in
many different healthcare contexts (see [32-34]), we are not aware of any that specifically
trained medical specialists in cancer genetics, although Houwink et al. developed and tested a
website to train general practitioners in the Netherlands in cancer genetics [7, 40]. Thus, our
website fills an important gap in the suite of training resources available for non-genetics
healthcare professionals in Australia and is one of the first internationally to specifically focus
on mainstreaming of germline testing for cancer genetics.
The current pilot study surveyed predominantly medical oncologists, surgeons and
oncology nurses who had completed the program in relation to satisfaction with, and
acceptability of, the online program as well as self-rated competence in communicating with
breast and ovarian cancer patients about genetic testing following program completion. The
majority of participants were satisfied with the information contained in the program, found
14

the program helpful and reported that they had gained new skills from the program relating to
communicating with breast and ovarian cancer patients about genetic testing. None reported
that the training program was too long, indicating that busy oncology healthcare professionals
did not find the time to complete the training onerous. Following completion of the training
program, most participants reported that they were confident in communicating with breast
and ovarian cancer patients about genetic testing. These findings demonstrate that the online
training program was successful in meeting its objectives.
Participants also made a number of suggestions for improvements including providing
training about genetic testing in other contexts, for example BRCA1/2-positive pancreatic
cancer as well as training which targets pathogenic variants in genes other than BRCA1/2.
These results indicate that a whole suite of training interventions may be needed to meet
oncology healthcare professionals’ current needs to cover the increased range of germline
testing in different cancers where testing is already being offered. Indeed, when this training
website was first developed, the intention was to be able to modify it and add more modules
to it, as more cancers could be tested under the Medicare Benefits Scheme in the future, e.g.
colorectal cancers. A web portal with a wide range of different modules for users to choose
from may be ideally suited to meet healthcare professionals’ needs. A core module with
generic content might be presented, together with specific modules that address diseasespecific issues. This approach has been shown to work well in other contexts [41]. The
current website and its evaluation will provide some guidance as to the possible contents of
individual modules comprising such web portals. Other suggestions for improvements made
by participants included emailing updates to the program to people who have completed the
program to allow them to keep their knowledge current. Other options for updating may
include regular webinars, where those who have previously completed the training program
are invited.
15

During the COVID-19 pandemic, online teaching has become more common and
acceptable due to restrictions on travel and conference attendance [42, 43]. It provides a costeffective strategy for dissemination of new knowledge and skills training that ensures
healthcare professional safety. Another approach has been to use videos in a webinar or have
an actor playing the role of the patient in webinars for interactions to be practiced, rather than
“live” at a central venue. This program could be adapted to such an approach. As genetic testing
results may also be delivered via telehealth, this approach allows participants to learn how to
use this medium effectively.
About one quarter of participants did either not believe that the videos in the program
were useful or were unsure. The videos featured experts in cancer genetics, rather than
professional actors, reflecting the low budget we had available.

It is possible that more

sophisticated videos, e.g. professionally produced videos featuring actors to play the role of
patients and healthcare professionals to engage users in experiential learning activities, might
have resulted in higher participant satisfaction. We have recently demonstrated that an online
training website with video-based patient vignettes using professional actors can be used
successfully to show exemplary clinician behaviours in the context of communication skills
training in oncology [38]. Similar videos could be produced for training in cancer genetics,
and such videos could be adapted for use in “live” webinars and training with actors. The
recent Australian survey of medical specialists regarding their continuing education needs
relating to genomic medicine shows that participants believed that experiential learning in
genomic medicine was necessary to develop the confidence and skills needed for clinical care
[22]. Hence, an important aim of future research should be to develop communication skills
training programs specific to cancer genetics incorporating experiential learning activities.
Such learning activities could incorporate watching videos and practicing with peers. Studies
using similar experiential learning have demonstrated that communication skills training of
16

oncologists increases the number of observable communication skills utilised by specialists in
both simulated and actual consultations following training [45, 46].
The limitations of this study should be mentioned. First, it is unknown how many
participants received the invitation to the study, and therefore it is not possible to report the
response rate and assess participation bias. Oncology healthcare professionals were asked
whether they had gained new skills from the program; however, this question should have been
asked differently given they have not yet had an opportunity to use these new skills in practice.
A follow-up assessment (e.g. six months after completion of the modules) would have been
helpful to assess whether there was a gain in skills. Participants were asked to self-rate
competence, and we did not objectively measure competence. Future studies should record
consultations involving patients to demonstrate actual increases in the quality of
communication and include direct assessments of patient outcomes as well as measurements
against published competencies [47]. Another limitation was that the modules were restricted
to genetic testing in the BRCA1/2 genes and did not include testing of other breast and ovarian
cancer genes. Given the promising results from this pilot study, future studies should include
randomised trials to evaluate whether the program changes clinical practice and improves
patient outcomes. Future studies should also assess whether the online program actually leads
to an increase in the use of genetic testing. Moreover, future studies should compare the effects
of online training to blended models that combine some face-to-face with online learning.
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Figure 1: Examples of reinforcing activities

26
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Table 1: Baseline characteristics of oncology healthcare professionals
Characteristics
Age (years)
18-29
30-39
40-49
50-59
60+
Gender
Female
Male
Professional background
Medical oncologist
Medical oncologist trainee
Gynaecological oncologist
Surgeon
Nurse
Oncology pharmacist
Place of practice
Metropolitan
Rural
Both
Public/Private sector practice
Public
Private
Both
Years of practice in current field
0-5
6-10
11-20
More than 20
How often do you discuss genetic testing with patients?
Never
1-5 times a year
6-10 times a year
11-20 times a year
> 20 times a year

28

(N=32)
N (%)
1 (3)
20 (62)
9 (28)
1 (3)
1 (3)
24 (75)
8 (25)
8 (25)
6 (19)
1 (3)
5 (16)
11 (34)
1 (3)
25 (78)
5 (16)
2 (6)
18 (56)
9 (28)
5 (16)
21 (66)
5 (16)
2 (6)
4 (13)
5 (16)
9 (28)
5 (16)
5 (16)
8 (25)

Table 2: Self-rated competence in communicating with breast and ovarian cancer patients
about genetic testinga
Statement

Somewhat Neither
disagree
agree nor
disagree
n (%)
n (%)
12 (39)
2 (7)

Strongly
disagree
n (%)

Before the training program, I 3 (10)
felt confident communicating
with breast and ovarian cancer
patients about genetic testing.
Now that I have completed the 0 (0)
training programme, I feel
confident in communicating
with breast and ovarian cancer
patients about genetic testing.
1 (3)
I feel confident that I will
use the skills I learned in
the training program.

a

Somewhat Strongly
agree
agree
n (%)

n (%)

11 (36)

3 (10)

0 (0)

2 (7)

19 (61)

10 (32)

0 (0)

3 (10)

13 (42)

14 (45)

The skills I learned in the
training program will allow
me to provide better patient
care.

0 (0)

0 (0)

3 (6)

15 (47)

16 (52)

The training program
prompted me to
critically evaluate my
own communication
skills in relation to
genetic testing.

1 (3)

4 (13)

0 (0)

16 (52)

10 (32)

Percentages may not add up due to rounding. One participant did not provide responses to any of the item.
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